Jared Saul, Global Head of Healthcare and Life Sciences Startups at AWS, discusses the healthcare industry with Andrew Goldberg, Co-founder and COO of HealthVerity. Goldberg notes that the COVID-19 pandemic has sped up many industry-wide trends, such as the inclusion of RWE (real world evidence) and […]
First Transgender Nominee Confirmed by Senate As Assistant Health Secretary
Rachel Levine has been confirmed to the Senate as assistant health secretary amid bipartisan support. In her previous role, she served as Secretary of the Pennsylvania Department of Health. She previously held roles as Physician General of Pennsylvania and Health Secretary of Pennsylvania. As the […]
Comparing High US Drug Prices to Rest of World is Flawed, Reference Pricing Not a Solution
There are five key points driving high drug prices in the US, including better access in the US and robust competition. As speculation builds regarding the implementation of reference pricing as a possible ameliorative measure, not all are onboard. Would reference pricing really lead to reduced […]
New Review on Inclusion of RWE in Regulatory Decisions
A new paper discusses the state of RWE (real world evidence) and RWD (real world data) in the context of pharmacoepidemiology. Important conclusions can be drawn from EHRs (electronic health records) and healthcare claims, among other sources. These types of data are being increasingly used in the […]
Fishawack Health Acquires Major HEOR and Market Access Firm PRMA Consulting
Fishawack Health has announced its acquisition of PRMA Consulting, a leading HEOR (health economics and outcomes research) firm with insight into market access in the US, Europe, and the Asia-Pacific. This move is expected to broaden the reach of Fishawack following its acquisition of US-based […]
High Powered Computational Tools Are Bringing Changes to Clinical Trial Design
As High-Performance Computing (HPC) becomes more widespread and accessible, even for relatively small companies, clinical trial design is expected to shift and evolve. Processes that used to take months of in-depth analysis now take days. Notably, statisticians are expected to adapt to these new […]
How Can Payers Outperform the Market?
A new whitepaper details the challenging facing payers in an increasingly competitive market. LexisNexis Risk Solutions recently partnered with HealthcareDive’s studioID to survey over 100 professionals working in payer organizations. These professionals highlighted the importance of having access […]
Will the FDA Kill French Dressing? Are Other Salad Dressings Safe?
The FDA (Food and Drug Administration) has announced its intention to edit the accepted definition of French dressing and the ingredients required call it “French” following a discussion with the Association for Dressings & Sauces. This move would expand the condiment’s definition and allow for […]
Clora and Scientist.com Announce Partnership to Fill Considerable Talent Gaps in Life Science Industry and Expedite R&D
HealthEconomics.Com’s parent company, Scientist.com, has announced a new partnership with Boston-based company Clora. Clora has extensive experience in recruiting talent within budget and time constraints. Together, these companies aim to discover, build and manage life science teams, including […]
Scientist.com Reveals Expanded HEOR, Value, and RWE Category, Good News for Both Researchers and Suppliers
Scientist.com, parent company of HealthEconomics.Com, has recently announces a rebranding initiative for its “Value, Evidence and Access Marketplace.” This online solution arm of the company connects researchers and suppliers in an efficient, streamlined process. Access to RWD (real world data) and […]
NICE Issues Ruling on Bladder Cancer Drug Keytruda
MSD’s Keytruda (pembrolizumab) is a second-line bladder cancer drug. It has been shown to improve survival. However, it has not been demonstrated to be effective in progression-free survival. NICE has determined that Keytruda should not be eligible for NHS funding. An alternative drug (Tecentriq) […]
Guide to Avoiding Clinical Supply Challenges in Clinical Trials
There are several important questions that arise when it comes to clinical supply. Neglecting this part of your study design can lead to serious consequences when it comes to your budget, timeline of the study, regulatory issues, and logistics. “Planning on using a CRO to support your next […]
COVID-19 Pandemic Brings Far-reaching Healthcare Consequences and Increased Disease Risk
A new whitepaper discusses how deferred care or a lack of care during the pandemic will drive high healthcare costs for payers and late-stage disease diagnoses by providers. Predictive analytics provide insight into the top three diseases expected to be diagnosed in 2021 and trends expected in […]
ICER Announces New Governance Board Members in Push to Improve Drug Pricing and Health Equity
ICER (the Institute for Clinical and Economic Review) has announced the election of two members to its Governance Board: Joy Lewis, MSW, MPH and Chris Jennings. Joy Lewis is Senior Vice President of the American Hospital Association’s health equity strategies arm and Chris Jennings is President and […]
Register Today for ISPOR’s HEOR Education Webinar
ISPOR is hosting a webinar on Tuesday, March 23rd at 11 AM Eastern Time. Join this free event to learn more about the organization’s strategy and priority changes related to HEOR (health economics and outcomes research). ISPOR’s Science Strategy series is designed to guide ISPOR topics and direction […]
Will States Look to ICER Reports in Legislative Measures to Regulate Drug Prices?
High drug prices are a national crisis. Policymakers in three different states (Washington, Maine, and Hawaii) have introduced price control legislation. Of note was the emphasis placed on independently run ICER’s reports and recommendations. ICER has been markedly critical of unjustified price […]
How Do Bioisimilars Drive High Drug Prices? Proposed Drug Policy Could Save Americans $360 Billion
One proposed solution for high drug prices in the United States is the use of biosimilars. According to Peter Bach, Director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering, along with Mark Trusheim, Strategic Director of the NEWDIGS drug development think tank at MIT, this […]
Democratic and Republican Voters Agree on Lowering Extreme Drug Prices
A recent poll suggests that President Biden needs to take firm action on skyrocketing prescription drug prices. Prescription drug price controls are one of the only bipartisan concerns where both Democrats and Republicans agree that the federal government needs to step in. According to Frederick […]
Will Washington State Take on Drug Distribution Role?
A new bill would give the state of Washington’s Health Care Authority the power to distribute generic drugs and insulin in an effort to haul in out-of-control drug prices. This move is one of many aimed at lowering costs, including importing drugs from Canada and implementing a health technology […]
Pfizer Executive Confident in COVID-19 Vaccine Price Increase, $175 per Dose Possible
Pfizer CFO Frank D’Amelio spoke about the outlook for the company’s COVID-19 vaccine. He’s confident that the current price of $19.50 per dose of the Pfizer-BioNTech vaccine will increase as the pandemic slows to reach prices of other vaccines—around $150 to $175 per dose. He also notes that while […]
The Impact of COVID-19 on Pharma Sales Representatives
As the COVID-19 pandemic continues, the typical day-to-day life of a pharma sales rep has drastically changed. Visiting hospitals to meet with physicians and travelling to conferences are both on hold. Some companies have turned to online options and have considered entirely eliminating sales rep […]
ICER Adds Members to Three Appraisal Councils to Boost Evidence Reviews
ICER (the Institute for Clinical and Economic Review) has added members to three independence appraisal councils: Midwest CEPAC (Midwest Comparative Effectiveness Public Advisory Council), CTAF (the California Technology Assessment Forum), and New England CEPAC (the New England Comparative […]
Cytel Webinar on Effectively Using RWD in Clinical Trials
The use of RWD (real world data) is on the rise. However, certain myths regarding when and how it can and should be used remain. A webinar sponsored by Cytel will discuss how to appropriately incorporate RWD into synthetic control arms. The webinar will take place on Thursday, March 25th at 11 AM […]
How Will Sale and Distribution of Generic Drugs in Washington State Affect Drug Prices?
Surging drug prices have led to widespread frustration across the United States. Washington state’s Senate recently passed drug pricing legislation allowing the state to purchase generic drugs, distribute them, and to manufacture them. To accomplish these goals, Washington state is expected to […]
PRMA Consulting Offers Insight Into US Drug Market and ICER Recommendations
PRMA Consulting has released an eBook detailing the major issues faced by pharmaceutical companies in the United States. Access to patients, reimbursement from payers, and navigating ICER recommendations all pose unique challenges. The guide also provides insight into prescription drug policy and […]
Panacea and IQVIA Host RWE and HEOR Webinar on Saturday, March 20th
A webinar on RWE (real world evidence) and HEOR (health economics and outcomes research) will take place on March 20th at 4:00 PM IST. Richa Goyal and Aditi Aggarwal of the HEOR division of IQVIA will share their insights regarding the widespread need for education in order to improve the healthcare […]
Syneos Health Communications Adds Three Senior Hires to Team
Syneos has added three high-profile hires to their team. Orrin Pollard will take on the role of Director of European Creative Expression. He has over 25 years of experience in leading health and wellness teams. Christina Pantelias will serve as Executive Vice President of Strategy, GSW New York […]
ICER to Investigate Treatments for Autoimmune Disease Myasthenia Gravis
ICER will determine the efficacy and economic outcomes of two treatments for autoimmune disease Myasthenia Gravis where neuromuscular junctions are weakened. It affects between 14 and 20 people per 100,000 in the US with a typical yearly cost of $15,675 for payers. Antibody fragment efgartigimod and […]
Workforce Requires Training to Bolster Value-Based Care and Healthcare Equity
Value-based care and equity require several healthcare components to be improved and expanded upon, including the development of the workforce. Serious issues in the healthcare field have only been worsened by the COVID-19 pandemic. In a recent article, the authors discuss how to improve equity in […]
Using Analytics to Understand Value-Based Pricing During COVID-19
Value-based prescription drug pricing agreements are increasing for many expensive and complex drugs. However, these agreements are becoming less used for some less complicated drugs. Understanding the underlying factors leading to this agreement using analytics software, among other tools, can […]
